Real lipid treatment journeys, shared anonymously
What people actually tried, what worked, what it cost, and how insurance handled it. Every field is optional and this isn't medical advice.
| Contributor | Diagnosis | Drug | Outcome | Would recommend | Payer | Coverage | Price |
|---|---|---|---|---|---|---|---|
| Maria_FLIllustrative example | Statin-intolerant | Atorvastatin | Stopped-side effects | No | Employer-sponsored | No prior auth needed | USD 10/mo |
| Maria_FLIllustrative example | Statin-intolerant | Ezetimibe | Not effective | Mixed | Employer-sponsored | No prior auth needed | USD 12/mo |
| Maria_FLIllustrative example | Statin-intolerant | Evolocumab (Repatha) | Well tolerated & effective | Yes | Employer-sponsored | Approved after appeal | USD 45/mo |
| Raj_TXIllustrative example | High Lp(a) | Rosuvastatin | Well tolerated & effective | Yes | Private insurance | No prior auth needed | USD 8/mo |
| Denise_AZIllustrative example | Familial Hypercholesterolemia | Atorvastatin | Effective w/ side effects | Mixed | Private insurance | No prior auth needed | USD 9/mo |
| Denise_AZIllustrative example | Familial Hypercholesterolemia | Inclisiran (Leqvio) | Well tolerated & effective | Yes | Private insurance | Approved after appeal | USD 150/mo |
Rows marked “Illustrative example” are not real submissions and are excluded from any future aggregate statistics.
What clinical trials found
Sourced from published trial data, not user submissions.
Atorvastatin
ApprovedStatin (HMG-CoA reductase inhibitor)
High-intensity statin, first-line therapy for most people with elevated LDL. Generic, widely available. TNT showed intensive atorvastatin dosing reduced major cardiovascular events versus lower-dose therapy.
TNT (Treating to New Targets)Rosuvastatin
ApprovedStatin (HMG-CoA reductase inhibitor)
High-intensity statin, generic. JUPITER showed rosuvastatin reduced cardiovascular events in people with normal LDL but elevated CRP, broadening who statins are considered for.
JUPITEREzetimibe
ApprovedCholesterol absorption inhibitor
Usually added to a statin when LDL goals aren't met on statin alone. IMPROVE-IT showed adding ezetimibe to statin therapy further reduced cardiovascular events after acute coronary syndrome.
IMPROVE-ITEvolocumab (Repatha)
ApprovedPCSK9 inhibitor (monoclonal antibody)
Injectable, typically every 2-4 weeks. Approved 2015. FOURIER showed evolocumab added to statin therapy further reduced cardiovascular events in people with established ASCVD.
FOURIERAlirocumab (Praluent)
ApprovedPCSK9 inhibitor (monoclonal antibody)
Injectable, typically every 2-4 weeks. Approved 2015. ODYSSEY OUTCOMES showed alirocumab reduced cardiovascular events after a recent acute coronary syndrome.
ODYSSEY OUTCOMESInclisiran (Leqvio)
ApprovedsiRNA (blocks PCSK9 production in the liver)
Injectable, only twice a year after the first two starter doses. Approved 2021. ORION trials showed sustained LDL reduction with infrequent dosing versus the every-2-4-week PCSK9 antibodies.
ORION-10 / ORION-11Bempedoic acid (Nexletol)
ApprovedATP-citrate lyase (ACL) inhibitor
Oral, once-daily pill, often used for statin-intolerant patients since it's not associated with the muscle-related side effects statins can cause. Approved 2020. CLEAR Outcomes showed reduced cardiovascular events in statin-intolerant patients.
CLEAR OutcomesLerodalcibep (Lerochol)
ApprovedPCSK9 inhibitor (third-generation, small recombinant fusion protein)
Once-monthly, self-administered injection, room-temperature stable for up to 3 months (most PCSK9 injectables need refrigeration). FDA-approved December 2025 for hypercholesterolemia including heterozygous FH, launched in the US in spring 2026 as a prefilled syringe, with an autoinjector following later in the year. A direct-to-patient cash program is available at $199/month.
LIBerate programRecent updates
- 2026-07-01·Trial result
Obicetrapib gets a positive opinion from Europe's drug regulator
The EMA's CHMP recommended approval of obicetrapib (alone and combined with ezetimibe) for primary hypercholesterolemia. A final EU decision is expected later in 2026. Not yet approved in the US; the Phase 3 cardiovascular outcomes trial reads out in 2027.
Source - 2025-12-15·FDA approval
FDA approves Lerochol (lerodalcibep), a third-generation once-monthly PCSK9 inhibitor
First PCSK9 inhibitor stable at room temperature for up to 3 months. Launched in the US in spring 2026 as a prefilled syringe, with an autoinjector to follow later in the year. A direct-to-patient cash program is available at $199/month.
Source - 2025-11-01·Trial result
Muvalaplin's Phase 3 outcomes trial begins enrolling
MOVE-Lp(a) will enroll over 10,000 people to test whether this first-in-class oral Lp(a) drug reduces cardiovascular events. Results aren't expected until 2031.
Source